fbpx
Connect with us

MedTech

Russia’s Sputnik V vaccine shows 94% efficacy in Bahrain

Inside Telecom Staff

Published

 on

Sputnik-V

Controversy has been the main headline stuck to Russia’s Sputnik V COVID-19 vaccine, with many countries either doubting its efficacy levels or brushing it off due to political tensions between western countries and Russia.

In parallel, Russia hasn’t done a good job marketing the drug since it was named after the Soviet Union’s and the world’s first artificial satellite launched into space back in 1957.

But still the Russian vaccine persisted and remains to be administered to people all around the world as we speak.

With that in mind, the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announced on Thursday data of the Ministry of Health of the Kingdom of Bahrain on the Russian Sputnik V coronavirus vaccine confirming its safety and high efficacy during the vaccination campaign in the country.

The efficacy study was conducted in Bahrain in accordance with WHO guidelines involving more than 5,000 subjects. Overall efficacy beyond 14 days after administering the second dose was estimated at 94.3 percent.

Analysis is based on the data collected between February and early May 2021.

“Sputnik V has demonstrated efficacy of 94.3 percent and high safety confirming the data collected in a number of other countries where it is used to protect the population against coronavirus. The Russian vaccine is an important part of Bahrain’s diversified national portfolio. Use of Sputnik V is making a significant contribution in mitigating the spread of coronavirus, resuming normal life and economic activity,” Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said in a statement.

The data of the Ministry of Health also demonstrates that 98.6 percent of all COVID-19 cases 14 days after receiving the second dose were mild among those vaccinated with Sputnik V.

Vaccination data indicates high safety of Sputnik V:

  • No serious adverse events associated with vaccination;
  • No deaths related to the vaccination;
  • No cerebral vein thrombosis (CVT) cases after vaccination.

“Our data has confirmed the high efficacy and safety of Sputnik V during its use in Bahrain. This vaccine is one of a number of approved vaccines made available free of charge to citizens and residents in the Kingdom. Sputnik V continues to play an important role in the Kingdom’s ongoing and successful vaccination campaign, with 81 percent of the eligible population vaccinated so far,” Faeqa Saeed Al-Saleh, Bahrain’s Minister of Health, highlighted. 

Sputnik V has a number of key advantages:

  • Efficacy of Sputnik V is 97.6 percent based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020, to March 31, 2021;
  • The vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
  • Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
  • The safety, efficacy, and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
  • There are no strong allergies caused by Sputnik V.
  • The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
Advertisement

We’re a diverse group of industry professionals from all corners of the world. Our desire is to provide a high-quality telecoms publication that caters to an international market, offering the latest and most relevant telecoms information to businesses, entrepreneurs and enthusiasts.

Continue Reading
Advertisement

MedTech

AI cancer diagnosis platform receives FDA Designation

Karim Husami

Published

 on

AI cancer diagnosis

The U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to Ibex Medical Analytics, a specialist in AI-powered cancer diagnostics, which will help fast track the clinical review and regulatory approval of its platform.

Granting such approval is given to technologies that have the potential to provide more effective treatment or diagnosis of life-threatening diseases.

The designation enables close collaboration with, and expedited review by the FDA, and provides formal acknowledgement of the Galen platform’s utility and potential benefit as well as the robustness of Ibex’s clinical program.

Oncology treatments

According to the National Cancer Institute, approximately 39.5 percent of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2015–2017 data).

“In 2020, an estimated 16,850 children and adolescents ages 0 to 19 will be diagnosed with cancer and 1,730 will die of the disease,” the institute noted.

An estimated 1,806,590 new cases of cancer will be diagnosed in the United States in 2020, it noted, and 606,520 people will die from the disease.

“Oncology treatments have made great strides, but to save more lives it is also essential to see technological advances in cancer diagnostics. Enhancing the accuracy of cancer diagnosis and improving the efficiency for the pathologist is paramount to improving quality and affordability of cancer care,” David Shulkin, MD, advisor to Ibex Medical Analytics said.

AI cancer diagnosis platform role

“Ibex’s AI platform has demonstrated success in helping pathologists worldwide improve care for patients with cancer. This FDA designation is an important step forward in making this technology broadly available in the United States,” David added.

That said, pathologists play an important role in the detection and diagnosis of disease, with their assessment being vital for correct treatment decisions in cancer care.

However, a rise in cancer prevalence and advances in personalized medicine have resulted in growing diagnostic complexity that significantly increases pathologists’ workloads.

As such, Ibex’s Galen platform uses Strong AI algorithms to help pathologists improve the quality of cancer diagnosis, implement real-time quality control, reduce diagnosis time, and boost productivity. It has already demonstrated outstanding outcomes in clinical studies and is deployed in labs worldwide where it is used as part of everyday clinical practice.

Joseph Mossel, chief executive officer and co-founder of Ibex Medical Analytics, said: “We are honored to have been granted the Breakthrough Device Designation. Ibex is committed to providing world class tools for pathologists to ensure every patient receives a timely and correct diagnosis, while supporting pathology labs and health systems to increase efficiency and accuracy. Our Strong AI technology is already in clinical use globally, making a real impact on patient care. We are proud to work closely with the FDA and look forward to continuing to collaborate with the agency as we accelerate our clinical program in the United States.”

Continue Reading

MedTech

Orange, AXA acquire majority stake in Moroccan HealthTech company

Inside Telecom Staff

Published

 on

HealthTech

Orange Middle East and Africa and AXA CIMA entities led by AXA Assurance Maroc announced on Monday a joint agreement to acquire a majority stake in DabaDoc, the Moroccan HealthTech company digitalizing access to healthcare in Africa, alongside the company’s founders.

DabaDoc – which was founded by Zineb Drissi-Kaitouni and Driss Drissi-Kaitouni earlier in 2014 – has developed solutions that are used by thousands of healthcare professionals in Morocco, Tunisia, and Algeria.

The agreement will allow both French companies to accelerate DabaDoc’s growth using their vast investment portfolios and network, particularly in Sub-Saharan Africa; the transaction is expected to close in the third quarter of 2021.

“As a responsible operator on the continent, we want to contribute to this major social challenge, especially during a pandemic. The deployment of this type of solution in the countries where we are present will greatly facilitate populations’ access to healthcare services, which is essential to the continent’s development,” Alioune Ndiaye, CEO of Orange Middle East and Africa, said in a joint statement.

With this acquisition, the French telco confirms its ambition of leading the line in multi-services digital operator in the region. Through its partnership with DabaDoc and relying on AXA’s globally recognized expertise in healthcare, Orange is positioned as a key player in HealthTech.

In parallel, this acquisition wouldn’t be the first investment AXA Assurance has placed in DabaDoc – with the first being in 2018 – but rather sends a message that the insurance company is looking to consolidate its partnership with the company to accelerate the digitalization and integration of its customers’ healthcare journey.

AXA will also aim to facilitate its policyholders’ interactions with healthcare professionals, notably via DabaDoc’s appointment booking and remote consultation infrastructure and network.

“This is one of the Group’s strategic priorities as part of the Driving Progress 2023 plan. This ambition is even stronger as we are facing an unprecedented health crisis. Through this partnership, we therefore aim to enable patients to access a better healthcare journey in Morocco and to support DabaDoc through its development in the CIMA countries as well,” Meryem Chami, CEO of AXA Assurance Maroc and AXA CIMA, highlighted.

In cementing this tri-party partnership, DabaDoc will benefit from the broad experience of AXA, one of the global leaders in health insurance, and Orange’s technological expertise and payment solutions to enable digital solutions to be developed that rapidly scale and benefit patients and the entire African healthcare ecosystem.

“Orange’s investment in DabaDoc and AXA’s renewed investment will strengthen DabaDoc’s growth ambitions through Orange and AXA’s presence in Africa and the Middle East. The pandemic has strengthened our belief that the digitalization of healthcare services is essential and inevitable,” Zineb Drissi-Kaitouni, co-founder and CEO of DabaDoc, noted in the statement.

Continue Reading

MedTech

Project launched to create medical grade for electronic components

Karim Husami

Published

 on

electronic components

A new project is in place in order to create a medical grade for electronic components. Through it, these players intend to provide a concrete response to a problem known to manufacturers of medical devices: the absence of a standard.

Tame-Component and its partners in electronics (Vishay, Exxelia, NCAB, TechCI), in medical devices (Carmat, FineHeart, UroMems), Tame-Component, launched after two years of preparations, the RECOME project (Reliability of Electronic COmponents for MEdical devices) whose main objective is to create a standard to meet the reliability needs of medical electronics.

“The idea is to bring together players in the sector in order to bring together the needs of manufacturers of electronic components, medical devices, users of these technologies as well as electronic subcontractors… This new medical grade will bring real added value to all stakeholders and will increase the reliability of current and future electronic medical devices,” Jean Bastid, director of Component BU at TRONICO, said.

Also, this project is the subject of a consortium bringing together TRONICO, Ouest Valorisation and the Laris laboratory (University of Angers) and is funded by the government as part of the recovery plan and by the Pays de la Loire region.

Bastid added: “Until now, component reliability had little impact, but today electronics failure has an immediate impact on the patient ranging from the need for emergency surgery to death. The issue of electronics reliability has therefore become a major issue for the marketing authorization of the equipment.

In recent years, medical devices have evolved rapidly, and electronics have taken a prominent place in the medical field.

The next step for Tame-Component is the optimisation and validation of reliability models in order to write the experimental standard which will serve as a reference for the desired medical grade.

One of its main objectives will be achieved when Tame-Component has defined a reference, an experimental standard on which all manufacturers of medical devices, equipment suppliers, electronic subcontractors can rely on their technological choices.

Continue Reading

Trending